Form 4: aTyr Pharma Director Paul Schimmel Acquires 50,000 Stock Options

Director Paul Schimmel acquired 50,000 stock options in aTyr Pharma, Inc. on May 1, 2025, according to a recent SEC filing.

Summary

• Paul Schimmel, a director of aTyr Pharma, Inc., acquired 50,000 stock options on May 1, 2025.
• The options have an exercise price of $3.34.
• The options vest fully on the earlier of May 1, 2026, or the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
• The options expire on May 1, 2035.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative outlook.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's securities. It provides transparency to the market regarding insider activity.

Stakeholder Impact

• The acquisition of stock options by a director may have a slight positive impact on shareholders, as it could signal confidence in the company's future.

Key Dates

Keywords

aTyr Pharma, Stock Options, Director, Paul Schimmel, SEC Filing, ATYR